Sinopharm (HKG:1099) attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.
Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 2.67 yuan.
Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.
The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.
Shares slipped 4% during Monday's afternoon trading.